Reactivity of Soluble Fibrin Assays with Plasmic Degradation Products of Fibrin and in Patients Receiving Fibrinolytic Therapy
Reactivity of Soluble Fibrin Assays with Plasmic Degradation Products of Fibrin and in Patients Receiving Fibrinolytic Therapy
复制标题
可溶性纤维蛋白测定与纤维蛋白血浆降解产物以及接受纤溶治疗的患者的反应性
DOI：
10.1055/s-0037-1614905
复制
发表时间：
1999
影响因子：
6.7
通讯作者：
C. Francis
中科院分区：
文献类型：
--
作者：
Bonnie McCarron;V. Marder;C. Francis
摘要 识别凝血酶和纤溶酶对纤维蛋白原作用的产物的能力对于患有血栓和纤维蛋白溶解疾病的患者非常重要。已经开发出针对“可溶性纤维蛋白”的新测定法，“可溶性纤维蛋白”代表除由凝血酶从纤维蛋白原形成的纤维蛋白肽以外的可溶性衍生物。这些检测要么是免疫学的，使用纤维蛋白特异性新表位的抗体，要么是功能性的，基于组织纤溶酶原激活剂（t-PA）介导的纤溶酶原向纤溶酶的转化中可溶性纤维蛋白的辅因子活性。由于纤维蛋白的血浆衍生物与可溶性纤维蛋白具有相同的结构特征，因此它们可能与可溶性纤维蛋白的测定发生反应。因此，我们制备了纤维蛋白的血浆消化物，并通过四种可溶性纤维蛋白测定法确定了反应程度。三种测定使用针对 α17-23 (A)、γ312-324 (B) 和 α17-78 (D) 处纤维蛋白特异性新表位的 Mab。第四个 (C) 基于 t-PA 辅因子活性。测试 A 和 C 表明与纤维蛋白降解产物具有显着的交叉反应性，并且含有最大衍生物的消化物显示出最大的反应性。交联纤维蛋白的血浆衍生物比非交联纤维蛋白的血浆衍生物具有更高的反应性。测试 B 和 D 证明与交联或非交联纤维蛋白的血浆衍生物具有最小的反应性。下肢外周动脉闭塞患者的样本在就诊时和溶栓治疗后八小时进行可溶性纤维蛋白、D-二聚体和纤维蛋白原的检测。使用测试 A、B、C 和 D 时，19 名患者中分别有 13、1、0 和 4 名患者出现升高，结果各不相同。纤溶治疗后，观察到可溶性纤维蛋白水平显着增加，比正常值高出 600 倍。通过测试 B 和测试 D 观察到基线水平之间存在很强的相关性，这表明与血浆衍生物的交叉反应性最小。溶栓治疗后，不同测定之间的相关性弱或没有相关性。结果表明，可溶性纤维蛋白的测定可能与纤维蛋白的血浆衍生物发生反应，在解释临床结果时必须考虑这一点。
Summary The ability to identify the products of thrombin and plasmin action on fibrinogen is important in patients with thrombotic and fibrinolytic disorders. New assays have been developed for “soluble fibrin” which represents soluble derivatives other than fibrinopeptides formed from fibrinogen by thrombin. These assays are either immunological, using antibodies for fibrin-specific neoepitopes, or functional and based on the cofactor activity of soluble fibrin in the tissue plasminogen activator (t-PA)-mediated conversion of plasminogen to plasmin. As plasmic derivations of fibrin share structural features with soluble fibrin, they may be reactive with assays for soluble fibrin. Therefore, we prepared plasmic digests of fibrin and determined the degree of reactivity with four soluble fibrin assays. Three assays used Mabs directed toward the fibrin-specific neoepitopes at α17-23 (A), γ312-324 (B) and α17-78 (D). A fourth (C) was based on t-PA co-factor activity. Tests A and C demonstrated marked crossreactivity with fibrin degradation products, and digests containing the largest derivatives showed greatest reactivity. Plasmic derivatives of crosslinked fibrin had greater reactivity than those of non-crosslinked fibrin. Tests B and D demonstrated minimal reactivity with plasmic derivatives of crosslinked or of non-crosslinked fibrin. Samples from patients with lower limb peripheral arterial occlusion were assayed for soluble fibrin, D-dimer and fibrinogen at presentation and eight hours after thrombolytic therapy. Variable results were seen at presentation with elevations in 13, 1, 0 and 4 of 19 patients using Tests A, B, C and D, respectively. After fibrinolytic therapy, marked increases in soluble fibrin levels were observed up to 600-fold above normal. A strong correlation between baseline levels was observed with Test B and Test D, which showed the least cross-reactivity with plasmic derivations. After thrombolytic therapy there were either weak or no correlations among the different assays. The results demonstrate that assays for soluble fibrin may react with plasmic derivatives of fibrin and this must be considered in interpreting clinical results.
登录
查看更多内容
链激酶后纤维蛋白肽 A 反常升高：尽管有强烈的纤维蛋白溶解，但血栓持续形成的证据。
影响因子：
24
作者：
Eisenberg,PR;Sherman,LA;Jaffe,AS
通讯作者：
Jaffe,AS
纤维蛋白血栓和可溶性血浆衍生物的凝血酶活性。
DOI：
--
发表时间：
1983
期刊：
The Journal of laboratory and clinical medicine
影响因子：
--
作者：
Francis,CW;MarkhamJr,RE;Barlow,GH;Florack,TM;Dobrzynski,DM;Marder,VJ
通讯作者：
Marder,VJ
影响因子：
20.3
作者：
K. Bauer;K. Bauer;R. Rosenberg;R. Rosenberg
通讯作者：
K. Bauer;K. Bauer;R. Rosenberg;R. Rosenberg
人交联纤维蛋白片段 E 的结构。
影响因子：
2.9
作者：
Olexa,SA;Budzynski,AZ;Doolittle,RF;Cottrell,BA;Greene,TC
通讯作者：
Greene,TC
在抗 DD ELISA 系统中纤溶激活后血浆的免疫反应性增加。
影响因子：
37.8
作者：
Francis,CW;Doughney,K;Brenner,B;Klingbiel,K;Marder,VJ
通讯作者：
Marder,VJ